 |
Endothelin receptor B antagonist |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant melanoma Stages IIB to IV |
| USA Market Approval | USA |
| USA Designation Date | 2016-01-21 00:00:00 |
| Sponsor | ENB Therapeutics, LLC;166 5th Avenue, 2nd Floor;New York, New York, 10010 |
| |
Endothelin receptor B antagonist |
|---|---|
| Trade Name | |
| Orphan Indication | Malignant melanoma Stages IIB to IV |
| USA Market Approval | USA |
| USA Designation Date | 2016-01-21 00:00:00 |
| Sponsor | ENB Therapeutics, LLC;166 5th Avenue, 2nd Floor;New York, New York, 10010 |